 |
|
Serotonin and Human MyoclonusRationale for the Use of Serotonin Receptor Agonists and Antagonists
Michael R. Pranzatelli, MD
Arch Neurol. 1994;51(6):605-617.
Abstract
This is a critical review of the serotonin hypothesis of myoclonus for the purpose of identifying new pharmacologic therapies. The literature on myoclonus and serotonin neuropharmacology reveals evidence for serotonergic abnormalities in some human myoclonic disorders, new serotonin receptor subtypes and data on their molecular structure and function, more selective drugs, and experimental evidence linking certain serotonin receptor subtypes with myoclonus. This article provides an overview of clinical experience with serotonergic drugs, new investigational drugs, and strategies for gathering data critical to linking particular receptor abnormalities and drugs with specific human myoclonic disorders. Such information will allow the use of receptor subtype-selective agonists and antagonists for the treatment of myoclonus.
Author Affiliations
From the Departments of Neurology, Pediatrics, and Pharmacology, The George Washington University, Washington, DC.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
24.7.3 Movement disorders other than Parkinson's disease
Barker and Burn
OTM 2011;5:med-9780199204854-chapter-med-9780199204854-chapter.
ABSTRACT
| FULL TEXT
Pathophysiology of Pediatric Movement Disorders
Sanger
J Child Neurol 2003;18:S9-S24.
ABSTRACT
Oral Pharmacotherapy for the Movement Disorders of Cerebral Palsy
Pranzatelli
J Child Neurol 1996;11:S13-S22.
ABSTRACT
Topical Review: Antidyskinetic Drug Therapy for Pediatric Movement Disorders
Pranzatelli
J Child Neurol 1996;11:355-369.
ABSTRACT
|
